BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24121175)

  • 1. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
    Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
    Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
    Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
    Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
    Esheba GE; Longacre TA; Atkins KA; Higgins JP
    Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
    Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
    Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra.
    Chaux A; Han JS; Lee S; Gonzalez-Roibon N; Sharma R; Burnett AL; Cubilla AL; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2760-7. PubMed ID: 24134931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder.
    Klopfer K; Delahunt B; Adamson M; Samaratunga H
    Anticancer Res; 2014 Nov; 34(11):6779-84. PubMed ID: 25368291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin.
    Bezerra SM; Lotan TL; Faraj SF; Karram S; Sharma R; Schoenberg M; Bivalacqua TJ; Netto GJ
    Hum Pathol; 2014 Aug; 45(8):1682-7. PubMed ID: 24925221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
    Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
    Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms.
    Gonzalez-Roibon N; Faraj SF; Munari E; Bezerra SM; Albadine R; Sharma R; Argani P; Allaf ME; Netto GJ
    Hum Pathol; 2014 Feb; 45(2):244-8. PubMed ID: 24315206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
    Lionti S; La Rocca L; Nunnari CM; Barresi V
    Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
    Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
    Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases.
    Siddiqui MT; Seydafkan S; Cohen C
    Diagn Cytopathol; 2014 Sep; 42(9):809-15. PubMed ID: 24578300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
    Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
    Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
    Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
    Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.